On July 28, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that Company Management will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023 (Press release, AC Immune, JUL 28, 2023, View Source [SID1234633486]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the Fireside chat, Dr. Andrea Pfeifer, CEO of AC Immune SA, will discuss the Company’s clinical stage active immunotherapy pipeline to treat and, ultimately, prevent Alzheimer’s and other neurodegenerative diseases.

The live Fireside chat will take place on August 8, 2023, at 9:30 am (EDT) / 3:30 pm (CEST). AC Immune’s Management will take investor meetings on the same day. A replay will also be available through the BTIG Virtual Biotechnology Conference platform.